While this approach has been used successfully to improve fertility in some forms of obesity (i.e., obesity associated with polycystic ovarian syndrome) it is less clear if these effects are due to the direct action of GLP‐1 agonists on the neuroendocrine systems that regulate energy balance and fertility or through actions on the periphery that, for instance, improve metabolic health via a reduction of inflammatory signals.77 Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.